BRIUMVI (ublituximab)

**Product type:** Human Prescription Drug

**Active ingredient:** UBLITUXIMAB

**Strength:** 150 mg/6mL

**Dosage form:** Injection, Solution, Concentrate

**Route:** Intravenous

**Labeler:** TG Therapeutics, Inc.

**Marketing category:** BLA (BLA761238)

**Pharmacologic class:** CD20-directed Antibody Interactions [MoA], CD20-directed Cytolytic Antibody [EPC]